Improving Protein Delivery and Circulation via FcRn Ligands

通过 FcRn 配体改善蛋白质递送和循环

• 批准号: 8353495
• 负责人: FRANCIS C. SZOKA
• 金额: $ 22.66万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-15 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8353495
• 关键词: Affect; Affinity; Amino Acid Sequence; Binding; Binding Proteins; Biological Assay; Blood Circulation; Catabolism; Cells; Child; Chimeric Proteins; Development; Dose; Drug Delivery Systems; Drug Kinetics; Elderly; Epithelial; Epithelial Cells; Escherichia coli; Frequencies; Goals; Human; Immunoglobulin G; Injection of therapeutic agent; Ligand Binding; Ligands; Lung; MHC Class I Genes; Mediating; Methods; Modeling; Mus; Organ; Patients; Peptides; Phage Display; Pharmaceutical Preparations; Property; Protein Engineering; Proteins; Pulmonary Circulation; Recombinant Proteins; Recombinants; Recycling; Research; Role; Route; Somatropin; Surface Plasmon Resonance; Testing; Therapeutic; Time; Tissues; Transgenic Mice; Translating; absorption; base; growth hormone deficiency; human disease; improved; in vivo; macromolecule; mouse model; neonatal Fc receptor; novel; patient population; polypeptide; protein B; protein aminoacid sequence; success; therapeutic protein; transcytosis

DESCRIPTION (provided by applicant): A number of challenges impede the more widespread use of proteins as drugs including: their rapid elimination from circulation and the need to dose proteins via injection. Strategies that overcome these limitations could decrease dosing frequency and improve patient convenience and compliance. Engineering proteins to interact with the MHC Class I-like neonatal Fc receptor (FcRn) represents a promising strategy to improve circulation time and enable alternative routes of protein administration. FcRn is expressed in several organs and tissues in which it serves a distinct role in the protection of IgG from catabolism and/or transport of IgG across epithelial barriers. Peptide sequences that bind to FcRn with moderate affinity have been identified by phage display and may be amenable for incorporation into proteins in order to improve their pharmacokinetic properties and enable pulmonary protein delivery. We will investigate factors that affect the circulation time and epithelial transcytosis of FcRn binding peptide-modified proteins as a general strategy to improve protein circulation and enable pulmonary protein delivery. Three specific aims will be aggressively pursued. Aim 1. (A) Synthesize peptides ligands for FcRn and confirm they bind and are transported by FcRn; (B) Generate recombinant FcRn binding fusion proteins in E. coli based upon sequences identified in Aim 1A and characterize their interaction with FcRn. Aim 2. Determine the relationship between FcRn binding, in vivo circulation time, pulmonary absorption, and pulmonary retention in a human FcRn transgenic mouse model. Aim 3. Evaluate the therapeutic potential of FcRn binding peptide-modified human growth hormone (hGH) in a murine model of growth hormone deficiency. Our studies will generate a better understanding of the factors that control internalization and transcytosis of cargos attached to an FcRn ligand. Success in this research could enable the development of new protein-based therapies with convenient routes of administration that could greatly improve treatment in problematic patient populations such as children and the elderly. PUBLIC HEALTH RELEVANCE: Improved PK and Delivery of Protein Modified with FcRn Binding Ligands Project Relevance Our goal is to engineer proteins to interact with FcRn and use them to define factors that affect FcRn mediated protein circulation and pulmonary absorption. Successful completion of the plan would result in a novel method to improve protein delivery and pharmacokinetics that could be translated into improved protein therapeutics for treating human disease.

描述（由申请人提供）：许多挑战阻碍了蛋白质作为药物的更广泛使用，包括：它们从循环中快速消除以及需要通过注射给药。克服这些限制的策略可以减少给药频率，提高患者的便利性和依从性。工程蛋白与MHC i类新生儿Fc受体（FcRn）相互作用代表了一种有希望的策略，可以改善循环时间并实现蛋白质给药的替代途径。FcRn在一些器官和组织中表达，在这些器官和组织中，FcRn在保护IgG中起着独特的作用